## Contents

**Program Faculty** ................................................................. i

**Sponsorship and CME Credit** ........................................... ii

**CME Activity Assessment and Evaluation** ........................... iii

**Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference**

**Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases**
Theresa A. Guise, Khalid S. Mohammad, Gregory Clines, Elizabeth G. Stebbins, Darren H. Wong, Linda S. Higgins, Robert Vessella, Eva Corey, Susan Padalecki, Larry Suva, and John M. Chirgwin .............. 6213s

**Genomics and Proteomics of Bone Cancer**
Aaron G. Marguiles, V. Suzanne Klimberg, Sudeepa Bhattacharyya, Dana Gaddy, and Larry J. Suva ........... 6217s

**Molecular Mechanisms of Action of Bisphosphonates: Current Status**
Anke J. Roelofs, Keith Thompson, Sharon Gordon, and Michael J. Rogers ..................... 6222s

**Biology of Bone Cancer Pain**
Michael J. Goblirsch, Pawel P. Zwołak, and Denis R. Clohisy ........................................ 6231s

**The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient’s Experience**
Charles S. Cleeland ................................................................. 6236s

**Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity**
Robert E. Coleman ................................................................. 6243s

**High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?**
Øyvind S. Bruland, Sten Nilsson, Darrell R. Fisher, and Roy H. Larsen ......................... 6250s

**Breast Cancer: Bisphosphonate Therapy for Metastatic Bone Disease**
Jean-Jacques Body ................................................................. 6258s

**Multistate Analysis of Skeletal Events in Patients with Bone Metastases**
Richard J. Cook and Pierre Major ........................................... 6264s

**New Potential Targets for Treating Myeloma Bone Disease**
G. David Roodman ................................................................. 6270s

**Wnt Antagonism in Multiple Myeloma: A Potential Cause of Uncoupled Bone Remodeling**
Roger N. Pearse ................................................................. 6274s

**Treatment for Myeloma Bone Disease**
Howard S. Yeh and James R. Berenson ........................................ 6279s

**Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer**

**Bone Metastasis**
Robert L. Vessella and Eva Corey ........................................... 6285s

**Src Inhibitors in Metastatic Bone Disease**
Brendan F. Boyce, Lianping Xing, Zhenqiang Yao, Teruhito Yamashita, William C. Shakespeare, Yihan Wang, Chester A. Metcalf III, Raji Sundaramoorthi, David C. Dalgarno, John D. Iuliucci, and Tomi K. Sawyer ........................... 6291s

**Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists**
Michael A. Carducci and Antonio Jimeno ........................................ 6296s

**Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer**
Trevor Powles, Eugene McGrothy, and Alexander Paterson ........................................... 6301s

**Future Treatment of Bone Metastases**
Allan Lipton ........................................................................... 6305s

**Skeletal Complications of Breast Cancer Therapies**
Angela Hirbe, Elizabeth A. Morgan, Özge Uluskan, and Katherine Weilbaecher ............. 6309s

**Treatment-Related Osteoporosis in Men with Prostate Cancer**
Matthew R. Smith ................................................................. 6315s

---

www.aacrjournals.org  
Downloaded from clinccancerres.aacrjournals.org on August 3, 2021. © 2006 American Association for Cancer Research.